KSH01-R02-101 Solid Tumors
ConditionSolid Tumor
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorTCRx Therapeutics Co.Ltd
About this trial
1. . safety and tolerance 2. . objective response rate
Eligibility criteria
Qualifiers
1) Voluntary participation in clinical research; Fully understand the study and voluntarily sign the informed consent form; Willing to follow and able to complete all test procedures;
2) Male or female, 18 to 70 years old (including boundary value);
3) Malignant solid tumors failed to receive standard treatment;
4) HLA-A * 02 is positive and tumor target is positive (the staining intensity of target tumor cells is divided into 0, 1+, 2+, 3+, and more than 30% of cancer cells express 2+or 3+positive as the target is positive)
Disqualifiers
6.1.1) Neutrophil count (ANC) is not lower than the lower limit of normal value of the center;
6.1.2) White blood cell (WBC) shall not be lower than the lower limit of normal value of the center;
6.1.3) Platelet count (PLT) shall not be lower than the lower limit of normal value of the center;
6.1.4) Hemoglobin (Hb) shall not be lower than 0.8 * LLN (lower limit of normal value);
Trial design
Treatments tested in this trial
- KSH01 injection
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov